The European Commission approved GlaxoSmithKline’s three-in-one inhaler Trelegy Ellipta for chronic lung disease.
The live video, real-time communications company (RTC) TokBox announced the results of its inaugural “Live Video Maturity Study.”
Amgen’s PSCK9 inhibitor Repatha continues to impress as a treatment for patients with peripheral artery disease (PAD) and a history of heart attacks. New data shows Repatha hit its primary endpoints and significantly reduced first-time cardiovascular events by 27 percent in PAD patients.
Barely a week after announcing it was moving into a new corporate headquarters, Sangamo Therapeutics announced that the company has dosed the first patient in its Phase I/II gene therapy trial.
New Haven, Conn.-based Arvinas expanded an ongoing licensing deal with Genentech. The agreement is to develop new drugs using Arvinas’ PROTAC technology. The original deal was inked in October 2015.
The FDA approved an electrical nerve stimulator designed to reduce the symptoms of opioid withdrawal.
Acorda Therapeutics Inc. said five people died in clinical trials for the company’s Parkinson’s disease drug, the latest in a series of setbacks for the drugmaker.
A combination of regulatory conditions, shifts in physician workplace demographics, and an increased reliance of highly specialized sales personnel has steadily eroded the traditional sales reps’ responsibilities and ability to manage the HCP practice relationship as a true SPOC.
Shanghai Pharmaceuticals Holding Co. agreed to buy Cardinal Health Inc.’s China drug distribution business for $557 million, winning a highly competitive auction in a move that will greatly expand its presence nationwide.
AstraZeneca achieved another milestone in rebuilding its drug portfolio with U.S. approval of Fasenra for severe asthma.
Swiss-based Novartis is showcasing four key drugs from the company’s late stage pipeline at an R&D and investor event in England.
Mylan reportedly let go between 200 and 300 people from its West Virginia operations.
Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.
The U.S. Food and Drug Administration warned about the usage of kratom, citing reports of 36 deaths, and said there is no reliable evidence to support its use to treat opioid withdrawal symptoms.
A unit of healthcare conglomerate Johnson & Johnson dropped a lawsuit it filed to block a copy of the company’s rheumatoid arthritis drug Remicade produced by South Korea’s Samsung Bioepis Co. Ltd. from being sold in the United States.
Novartis’ generics division Sandoz said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab.
U.S. regulators approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.
Shares of Zymeworks shot up more than 33 percent after the company announced a licensing deal with Janssen Biotech to develop six bispecific antibodies.
Argos Therapeutics announced positive interim data for the company’s kidney cancer drug Rocapuldencel-T from a Phase III clinical trial.
Novartis’ canakinumab reduced cardiovascular risk by 25 percent in subgroup of CANTOS Phase III trial participants
Novartis announced results from a new analysis of the Phase III CANTOS study presented by Dr. Paul Ridker at the American Heart Association (AHA) Scientific Sessions 2017 and published simultaneously in The Lancet.